SMS Lifesciences Jumps 17%

  Published 10 months ago

SMS Lifesciences shares soar 17% after U.S. FDA clears Telangana facility with no regulatory action indicated in inspection.

  • API unit gets “voluntary action indicated” rating; no regulatory action expected post-inspection report from the U.S. FDA.
  • Stock sees its strongest day since August 2024, moving above key 50, 100, and 200-day moving averages.
  • Trading volume surges 70 times normal; SMSL now up 13.4% year-to-date after recent session gains.

You might like these

RBI Says Inflation Battle Not Over

Malaysia Extends Biocon Biologics Insulin Contract

Bharti Airtel Rises on Strong Growth, CLSA Analysis

India Cements Reports Q1 Loss

Satin Creditcare Adds Top Directors for 2025 Expansion

Vodafone Idea Q1 FY26 Results

India's Power Capacity Soars 90% to 475 GW in a Decade

News that matters the most ⚡